


Impact of vitamin C on genistein-induced cell death in prostate cancer

1st Electronic Conference on Molecular Science




Toluleke Oloruntobi Famuyiwa

09/20/2015

Introduction




Normal Prostate



Enlarged Prostate

Stages of Prostate Cancer


Stages of Prostate Cancer





Key statistics of prostate cancer

- * Prostate cancer(PCa) is the most common cancer in American men.
- * Estimated 220,800 new cases and 27,540 cancer-related deaths in 2015.
- * About 1 in every 7 men will be diagnosed with PCa during a lifetime.
- * About 6 cases in 10 are diagnosed in men aged 65 or older.
- * The average age at the time of diagnosis is about 66.

Treatment options of prostate cancer



Adjuvant therapy / combination of two therapies



5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one
(**genistein**, isoflavone)

Objective




The Purpose of this study was to:

Investigate and determine the potential therapeutic additive effect of genistein and vitamin C on prostate cancer


Null Hypothesis

Combine treatment of genistein and vitamin C will not cause more cells to die by apoptosis than genistein only.

Materials and methods



Pictures of cancer cells after treatment




24hrs 40uM
vitamin C

Pictures of cancer cells after treatment



24hrs 40uM
genistein

Pictures of cancer cells after treatment



24hrs (40uM vitamin C +
40uM genistein)

MTT Assay result




Fig A

IC-50 of vitamin C = 40uM

IC-50 of genistein = 28uM

Higher concentration of vitamin C is needed to kill 50% of LNCaP cells.







Fig B



NBT Assay result

Absorbance Value Percentages of Genistein in NBT Assay at 630 nm



Picture of LNCaP cells few minutes before treatment




4th day few minutes before treatment with drug



Cells were seeded into the 96-well MTP at 100ul on the 3rd day, cells treated when they reached 80% of confluence on 4th day and MTT assay performed on the 5th day .

Pictures of LNCaP cells 24hrs after treatment




Control



Vitamin C at 40uM concentration

Pictures of LNCaP cells 24hrs after treatment



Gen at 30uM + Vitamin C at
40uM

Third set of result





1st day of cell culture



4th day of cell culture


MTT assay

The Absorbance Value Percentages of LNCaP Cells Treated with Vitamin C, Genistein, or Combination (Constant Concentration of 40uM Vitamin C) Treatments in MTT Assay at 490 nm



Level of significance = 0.05 and p value of t-test = 0.11

Fluorescence assay of combination treatment showing qualitative result




80uM genistein + 70uM vitamin C




50uM genistein + 70uM vitamin C

Quantitative result of florescence assay



Genistein 10uM + vitamin C 40uM




Genistein 70uM + vitamin C 40uM




Control

Quantitative result of florescence assay




10uM genistein single treatment



70uM genistein single reatment

Percentage of Apoptosis, Necrotic and Living cells in the treatment groups



P value = 0.0003

Level of significance = 0.05

Ratio of Apoptosis to Necrosis in each treatment

Treatment	% Apoptosis	% Necrosis	% Apoptosis/ %Necrosis
Control	0	0	0
10uM of genistein	48	17	$2.8 = 3$
70uM of genistein	43	40	$1.1 = 1$
10uM of genistein + 40uM of vitamin C	48	2	$24.8 = 25$
30uM of genistein + 40uM of vitamin C	48	4	12
70uM of genistein + 40uM of vitamin C	62	6	$10.3 = 10$

Conclusion

- * P value of chi-square test = 0.0003 and the level of significance is 0.05
- * Reject the null hypothesis
- * Fluorescence assay shows different number of apoptotic death at different combination concentrations.
- * Decrease in absorbance reflects a decreased level of intracellular ROS
- * The order of effectiveness of treatment is (Gen 10uM + Vit C 40uM) > (Gen 30uM + Vit C 40uM) >(Gen 70uM + Vit C 40uM) >> 10uM genistein only > 70uM genistein only.

References

- * America Cancer Society (2013), Vitamin C.
- * American Cancer Society <http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics>; 2015.
- * Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. *Biochim Biophys Acta* (2012) 1826(2):443–57.
- * Hoffman R (2011). Screening for prostate cancer. *N Engl J Med*, 365, 2013-19.
- * James Kumi-Diaka, Saheed Oluwasina Oseni, Toluleke Famuyiwa, Rolando Branly(2015) Therapeutic impact of vitamin C on the anticancer activities of genistein isoflavone in radio sensitized LNCaP prostate cancer. *J. Cancer Prevention and Current Research*. Accepted – Research Article. JCPCR-15-RA-166 2015.
- * Parrow NL, Leshin JA, Levine M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. *Antioxid Redox Signal* (2013) 19(17):2141–56.
- * Verim L, Yildirim A, Basok EK, et al (2013). Impact of PSA and DRE on histologic findings at prostate biopsy in Turkish men over 75 years of age. *Asian Pac J Cancer Prev*, 14, 6085-8.
- * Yang Y, Karakhanova S, Werner J, Bazhin AV(2013) Reactive oxygen species in cancer biology and anticancer therapy. *Curr med chem factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res* 5(1):21–33.

Acknowledgement

Department of Biological Sciences of Florida Atlantic University





THANK
YOU!